Enhancing cancer targeting and anticancer activity by a stimulus-sensitive multifunctional polymer-drug conjugate

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery

Background:

• Anticancer drugs face challenges like poor solubility, low tumor targeting, and drug resistance.
• Doxorubicin (DOX) is an effective anticancer drug but suffers from limited clinical application due to these issues.

Purpose of the Study:

• To develop a novel drug delivery platform to enhance tumor targeting and efficacy of doxorubicin (DOX).
• To overcome limitations of conventional chemotherapy, including poor physicochemical properties and severe side effects.

Main Methods:

• Self-assembly of a polymer-drug conjugate (PEG-ppTAT-DOX) comprising polyethylene glycol (PEG), a matrix metalloproteinase 2 (MMP2)-sensitive peptide linker, a cell-penetrating peptide (TAT), and doxorubicin.
• Utilizing PEGylation for reduced non-specific interactions, MMP2-mediated PEG shielding/unshielding for tumor targeting, and TAT for cell internalization and endosomal escape.

Main Results:

• The PEG-ppTAT-DOX conjugate formed nanoparticles with enhanced tumor targetability and cell internalization.
• The platform demonstrated TAT-mediated nuclear translocation, inhibited drug efflux, and improved intracellular drug distribution.
• Potentiated anticancer activity was observed compared to traditional nanocarriers.

Conclusions:

• The developed polymer-drug conjugate offers a simple yet multifunctional approach for targeted drug delivery.
• This platform shows significant potential for enhancing chemotherapy efficacy and reducing side effects in cancer treatment.